Jul 31, 2020
MediSieve is a Semi-Finalist of the EIT Health Catapult
MediSieve won the regional round out of 42 start-ups in the EIT Health Catapult Semi-finals.
LONDON – July 31, 2020 – Out of 42 start-ups in the European Institute of Innovation & Technology (EIT) Health Catapult Semi-finals MediSieve won the regional round. EIT is one of the leading investment networks that is transforming the way healthcare is delivered in Europe, is concerned with changing lives and making new leaps in healthcare that put the patient front and centre.
The idea behind the EIT is that innovation flourishes best when the right people are brought together to share expertise. The organasition employs the so called ‘knowledge triangle’: the principle that when experts from business, research and education work together as one, an optimal environment for innovation is created. EIT blurs the borders between more than 150 Health Care Partner organisations and thousands of start-ups and entrepreneurs, bringing together the brightest minds in healthcare to answer some of the biggest health challenges Europe faces.
The EIT Health Catapult, currently in its fifth year of operation, is a training and competition programme that boosts the development of European health start-ups by exposing them to top quality experts and international investors. The businesses receive training from experts, meet international investors and corporates, and compete in pitch contests for a chance to enter the finals in December. After entering the semi-finals the start-ups are teamed up with mentors which review and optimise the pitch plan to enhance the business's ability to perform in front of top-level investors. In Autumn, all Start-ups pitch in front of an international, high-profile jury and an audience of experienced corporate representatives, experts and investors. 21 start-ups will be selected to continue on to the finals.
MediSieve has already been named a Gold Company before! Being named a Semi-Finalist means a lot for the company, the expert advice wil be implented into company's practices to advance its business strategy, attract investors as well as network with other participants. MediSieve's CEO George Frodsham has said:
"It is a great honour to be named as a semi-finalist amogst so many brilliant start-ups! This means a lot both for the company in terms of development and investment possibilities as well as for the team. It is always motivating to receive recognition from such an established network of professionals!"
More about the competition:
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: